Zepbound
E133648
Zepbound is a prescription weight-loss medication developed by Eli Lilly that uses the GLP-1/GIP agonist tirzepatide to help adults with obesity or overweight manage their weight.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Zepbound canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168571 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Zepbound Context triple: [Eli Lilly and Company, notableProduct, Zepbound]
-
A.
Zyvex
Zyvex is a pioneering nanotechnology company known for its early work in molecular nanotechnology and advanced manufacturing.
-
B.
Zeb
Zeb is a central character in Margaret Atwood's dystopian novel "MaddAddam," known for his complex past and role in the post-apocalyptic narrative.
-
C.
The Buds
The Buds is a popular nickname for the Toronto Maple Leafs, the historic NHL franchise based in Toronto, Ontario.
-
D.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
E.
Philortyx
Philortyx is a genus of New World quails known for their ground-dwelling habits and occurrence in scrub and grassland habitats of the Americas.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Zepbound Target entity description: Zepbound is a prescription weight-loss medication developed by Eli Lilly that uses the GLP-1/GIP agonist tirzepatide to help adults with obesity or overweight manage their weight.
-
A.
Zyvex
Zyvex is a pioneering nanotechnology company known for its early work in molecular nanotechnology and advanced manufacturing.
-
B.
Zeb
Zeb is a central character in Margaret Atwood's dystopian novel "MaddAddam," known for his complex past and role in the post-apocalyptic narrative.
-
C.
The Buds
The Buds is a popular nickname for the Toronto Maple Leafs, the historic NHL franchise based in Toronto, Ontario.
-
D.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
E.
Philortyx
Philortyx is a genus of New World quails known for their ground-dwelling habits and occurrence in scrub and grassland habitats of the Americas.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
brand name drug
ⓘ
prescription medication ⓘ weight-loss medication ⓘ |
| activeIngredient |
tirzepatide
ⓘ
linked to:
Mounjaro
|
| ATCCode | A10BX16 ⓘ |
| belongsToCompanyPortfolio | Eli Lilly obesity portfolio ⓘ |
| boxedWarning | risk of thyroid C-cell tumors ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
constipation ⓘ diarrhea ⓘ nausea ⓘ vomiting ⓘ |
| companyHeadquartersCity | Indianapolis ⓘ |
| companyHeadquartersCountry |
United States
ⓘ
linked to:
United States of America
|
| contraindication |
multiple endocrine neoplasia syndrome type 2
ⓘ
personal or family history of medullary thyroid carcinoma ⓘ |
| countryOfApproval |
United States
ⓘ
linked to:
United States of America
|
| dateOfFDAApproval | 2023-11 ⓘ |
| developer | Eli Lilly and Company ⓘ |
| dosingFrequency | once weekly ⓘ |
| formulation | solution for injection in pre-filled pen ⓘ |
| hasDrugClass |
GIP receptor agonist
ⓘ
GLP-1 receptor agonist ⓘ |
| hasMechanismOfAction | dual GIP and GLP-1 receptor agonist ⓘ |
| indication |
chronic weight management
ⓘ
obesity in adults ⓘ overweight in adults with weight-related comorbidities ⓘ |
| intendedUse |
to improve weight-related health conditions
ⓘ
to reduce body weight ⓘ |
| manufacturer | Eli Lilly and Company ⓘ |
| regulatoryAgency |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| regulatoryStatus | FDA-approved ⓘ |
| relatedDrug | Mounjaro ⓘ |
| requires | prescription ⓘ |
| requiresLifestyleModification |
increased physical activity
ⓘ
reduced-calorie diet ⓘ |
| requiresMonitoring |
gastrointestinal adverse reactions
ⓘ
signs of pancreatitis ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| sharesActiveIngredientWith | Mounjaro ⓘ |
| storageCondition | refrigerated ⓘ |
| targetPopulation |
adults with obesity
ⓘ
adults with overweight ⓘ |
| therapeuticArea |
metabolic disorders
ⓘ
obesity treatment ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Zepbound Description of subject: Zepbound is a prescription weight-loss medication developed by Eli Lilly that uses the GLP-1/GIP agonist tirzepatide to help adults with obesity or overweight manage their weight.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
Eli Lilly and Company (former executive roles prior to governorship)